BT-549

BT-549 (Breast Cancer CDX Model) 

The BT-549 breast cancer cell line was derived from a patient with invasive ductal carcinoma. It is classified as a triple-negative breast cancer (TNBC) model, lacking ER, PR, and HER2 expression. This aggressive subtype is associated with poor outcomes and limited targeted therapy options. BT-549 is widely used to explore new treatments for TNBC. 

Key Features: 

• Derived from invasive ductal carcinoma. 

• Triple-negative breast cancer (ER–, PR–, HER2–). 

• High tumorigenic potential in xenografts. 

• Models aggressive TNBC biology. 

Applications: 
BT-549 supports studies of TNBC progression and therapeutic response. It is commonly applied in evaluating novel chemotherapies and targeted strategies. Researchers use it to explore mechanisms of drug resistance and identify biomarkers. Its TNBC phenotype makes it highly relevant for translational oncology research.